Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ramipril

FDA-approved product (capsule, oral), marketed as Altace, Ramipril, Vostally.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ramipril
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myocardial infarction
  • Cardiovascular disease
  • Congestive heart failure
  • Coronary artery disease
  • Diabetes mellitus
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Ace inhibitors, plain
FDA pharmacologic class
Angiotensin Converting Enzyme Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ramipril in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ramipril with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The International Polycap Study 3 (TIPS-3)

    NCT01646437 · start 2012-06

    Registered record
    Registry ID
    NCT01646437
    Conditions
    Cardiovascular Disease; Fractures; Cancers
    Interventions
    Polycap; Aspirin; Vitamin D; Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06
    Completion
    2021-08-30
    Enrolment
    7,793

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease; Fractures; Cancers
    InterventionPolycap; Aspirin; Vitamin D; Matching Placebo
    PhasePhase 3
    Registry statusCompleted

  • Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure

    NCT01829880 · start 2011-10

    Registered record
    Registry ID
    NCT01829880
    Conditions
    Chronic Heart Failure; Cachexia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2011-10
    Completion
    2013-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure; Cachexia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?

    NCT01437371 · start 2011-08

    Registered record
    Registry ID
    NCT01437371
    Conditions
    Heart Failure
    Interventions
    - Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-08
    Completion
    2014-06
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    Intervention- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.
    PhasePhase 3
    Registry statusCompleted

  • Doxazosin and Ramipril in Hypertension

    NCT02901977 · start 2011-03

    Registered record
    Registry ID
    NCT02901977
    Conditions
    Hypertension
    Interventions
    Ramipril; Doxazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2015-04
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionRamipril; Doxazosin
    PhasePhase 4
    Registry statusCompleted

  • The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

    NCT01432106 · start 2011-02

    Registered record
    Registry ID
    NCT01432106
    Conditions
    Hypertension; Metabolic Syndrome
    Interventions
    Aliskerin/Valsartan and Rampiril
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2011-02
    Completion
    2012-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Metabolic Syndrome
    InterventionAliskerin/Valsartan and Rampiril
    PhasePhase 1
    Registry statusWithdrawn

  • To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

    NCT01302899 · start 2011-01

    Registered record
    Registry ID
    NCT01302899
    Conditions
    Non-diabetic Nephropathy
    Interventions
    Aliskiren; Placebo to Aliskiren; Hydrochlorothiazide (HCTZ); Placebo to Hydrochlorothiazide (HCTZ); Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-01
    Completion
    2011-12
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-diabetic Nephropathy
    InterventionAliskiren; Placebo to Aliskiren; Hydrochlorothiazide (HCTZ); Placebo to Hydrochlorothiazide (HCTZ) +1 more
    PhasePhase 2
    Registry statusTerminated

  • Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol

    NCT01362218 · start 2010-10

    Registered record
    Registry ID
    NCT01362218
    Conditions
    Elevated LDL Cholesterol
    Interventions
    Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril); Simvastatin, ramipril, acetylsalicylic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-10
    Completion
    2012-04
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionElevated LDL Cholesterol
    InterventionCardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril); Simvastatin, ramipril, acetylsalicylic acid
    PhasePhase 2
    Registry statusTerminated

  • A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure

    NCT01005290 · start 2009-10

    Registered record
    Registry ID
    NCT01005290
    Conditions
    Hypertension
    Interventions
    Combination pill; Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-10
    Completion
    2010-10
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionCombination pill; Ramipril
    PhasePhase 2
    Registry statusTerminated

  • A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol

    NCT01004705 · start 2009-09

    Registered record
    Registry ID
    NCT01004705
    Conditions
    Elevated LDL Cholesterol
    Interventions
    Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),; Simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-09
    Completion
    2011-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionElevated LDL Cholesterol
    InterventionCardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),; Simvastatin
    PhasePhase 2
    Registry statusTerminated

  • Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

    NCT00939588 · start 2009-07

    Registered record
    Registry ID
    NCT00939588
    Conditions
    Hypertension
    Interventions
    Aliskiren/ Valsartan; Telmisartan/ Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07
    Completion
    Not recorded
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAliskiren/ Valsartan; Telmisartan/ Ramipril
    PhasePhase 2
    Registry statusCompleted

  • Remission Clinic in Proteinuric Chronic Nephropathies

    NCT02721342 · start 2009-06

    Registered record
    Registry ID
    NCT02721342
    Conditions
    Chronic Kidney Disease
    Interventions
    Ramipril, Irbesartan and Atorvastin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2009-06
    Completion
    2022-11
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    InterventionRamipril, Irbesartan and Atorvastin
    PhaseNot recorded
    Registry statusUnknown

  • Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure

    NCT00923156 · start 2009-05

    Registered record
    Registry ID
    NCT00923156
    Conditions
    Heart Failure
    Interventions
    aliskiren; ramipril; Placebo to aliskiren; Placebo to ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-05
    Completion
    2011-02
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    Interventionaliskiren; ramipril; Placebo to aliskiren; Placebo to ramipril
    PhasePhase 2
    Registry statusCompleted

  • Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment

    NCT00741585 · start 2008-09-01

    Registered record
    Registry ID
    NCT00741585
    Conditions
    Essential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    Interventions
    Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09-01
    Completion
    2018-06-30
    Enrolment
    21,983

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    InterventionAny antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    PhasePhase 4
    Registry statusCompleted

  • Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

    NCT00772577 · start 2008-08

    Registered record
    Registry ID
    NCT00772577
    Conditions
    Hypertension
    Interventions
    Aliskiren Hydrochlorothiazide; Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-08
    Completion
    2009-03
    Enrolment
    386

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAliskiren Hydrochlorothiazide; Ramipril
    PhasePhase 4
    Registry statusCompleted

  • Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter

    NCT00736294 · start 2008-07

    Registered record
    Registry ID
    NCT00736294
    Conditions
    Atrial Fibrillation; Atrial Flutter
    Interventions
    Ramipril; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-07
    Completion
    2015-03
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Atrial Flutter
    InterventionRamipril; Placebo
    PhasePhase 3
    Registry statusTerminated